Research
Hormonal
Tirzepatide is a novel treatment option for Type 2 diabetes mellitus (T2DM) that may benefit individuals with cardiovascular disease or heart failure.
Tirzepatide may be considered for T2DM patients with cardiovascular concerns.
StrongSupportsmedium confidence
Tirzepatide is a dual agonist of glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptors, constituting a novel treatment option in T2DM.
Why this rating
The abstract discusses current evidence, suggesting a strong basis for the claim.
Source
Tirzepatide for the Treatment of Heart Failure in Type 2 Diabetes Mellitus: (SUR)PASS, or Not?
Dimitrios Patoulias et al. · Future Cardiology · 2023
DOI 10.2217/fca-2022-0112
reviewCited 4×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →